Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Proximal Optimization Technique in Unprotected LMCA

Proximal optimization technique (POT) has been recommended as a standard strategy in bifurcation lesions because it facilitates proper stent implantation and apposition in the proximal main vessel, according to the European Bifurcation Club.

POT en el TCI no protegido

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery (LMCA) has specific characteristics, and the long-term impact of this strategy has not been evaluated on follow-up.

Researchers conducted an analysis of 162 patients who underwent unprotected LMCA PCI. Of those, 99 (61.1%) underwent the POT, while 63 completed the procedure without POT.

The primary endpoint was a bifurcation-oriented composite of events (PEP BOCE) that included cardiac death, target-bifurcation infarction (TBI), and target-bifurcation- revascularization (TBR).

The mean age was 75 years, and 75% of subjects were men. Overall, 19% had diabetes, 67% had hypertension and 47% had undergone previous PCI.

Additionally, 89% had acute coronary syndrome, while silent ischemia and stable chronic syndromes were less frequent. Ejection fraction was 48%.

Read also: Post TAVR Long Term Outcomes in Patients with Chronic Inflammatory Disease.

About 39% of the cases were true bifurcations. Femoral access was used in 81% of cases, and the use of intracoronary imaging was low (16% for optical coherence tomography [OCT] and 1% for intravascular ultrasound [IVUS]).

At the 5-year follow-up, the PFP BOCE favored those who underwent the POT (20% vs. 37%, hazard ratio [HR]: 0.42 [0.22-0.80], p=0.009). There was no difference in cardiac mortality, TBI or TBR, as well as in stent thrombosis. The need for any revascularization was greater in those who did not undergo the POT (25% vs. 32%, p=0.008).

In the multivariate analysis, the use of POT was a strong predictor of BOCE, cardiac death, need for any revascularization, and non-cardiac death.

Conclusion

The POT improves evolution. These findings strongly support the routine use of POT in patients undergoing unprotected LMCA PCI.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Proximal optimization technique and percutaneous coronary intervention for left main disease: POTENTIAL‐LM.

Reference: Corentin Volet MMed, et, al. Catheter Cardiovasc Interv. 2024;103:340–347.      


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...